AbbVie: Q3 2026 earnings include $216 million IPR&D and milestones expense

AbbVie Inc.'s Q3 2026 GAAP and adjusted earnings include $216 million in bought in-process research and development and milestones expense. The company's full-year 2026 adjusted diluted EPS guidance range, including bought IPR&D, is $13.76-$13.96. The Q3 2026 adjusted diluted EPS guidance range including bought IPR&D is $3.73-$3.77.